Welcome to our dedicated page for Amicus Therapeut SEC filings (Ticker: FOLD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Amicus Therapeutics, Inc. (NASDAQ: FOLD) SEC filings page on Stock Titan provides access to the company’s official disclosures as a rare disease biotechnology issuer. Amicus describes itself as a global, patient-dedicated biotechnology company focused on discovering, developing and delivering medicines for people living with rare diseases, including Fabry disease and late-onset Pompe disease.
Key filings for FOLD include current reports on Form 8-K that summarize material events and financial updates. For example, Amicus has filed 8-K reports to furnish press releases announcing quarterly financial results for periods ended June 30, 2025 and September 30, 2025. These filings identify the company’s common stock as listed on NASDAQ under the symbol FOLD and outline that the information provided under Item 2.02 (Results of Operations and Financial Condition) is furnished rather than filed for certain liability purposes.
Through its periodic reports and exhibits, Amicus details net product revenues for Galafold (migalastat) and Pombiliti (cipaglucosidase alfa-atga) + Opfolda (miglustat), operating expenses, non-GAAP measures and cash position. These documents also describe the company’s focus on rare disease medicines and provide context for its commercial performance and research investments.
Investors can also expect SEC filings related to significant corporate transactions. On December 19, 2025, Amicus and BioMarin Pharmaceutical Inc. announced a definitive agreement for BioMarin to acquire Amicus in an all-cash transaction, a development that would typically be reflected in transaction-related filings and proxy materials as the process advances, subject to regulatory and stockholder approvals.
On Stock Titan, Amicus filings are supplemented by AI-powered tools that help explain the content and structure of documents such as 8-Ks, quarterly reports and, when available, annual reports and proxy statements. Users can review real-time updates from EDGAR, track how Amicus reports on its rare disease portfolio and commercial performance, and examine the regulatory record that underpins analysis of FOLD as a biotechnology stock.
Bradley Campbell reported sales of Common stock under 10b5-1 plans. The filing lists executed sales of 75,000 shares on 01/20/2026 for $1,073,182.50, 70,426 shares on 12/15/2025 for $763,509.39, and 7,500 shares on 12/15/2025 for $82,500.00.
The broker listed is Morgan Stanley Smith Barney LLC. The filing also shows 22,500 Restricted and Performance Stock Units dated 01/03/2021 as securities to be sold.
Amicus Therapeutics files its annual report highlighting a pending all-cash acquisition by BioMarin and continued growth in rare-disease therapies. Under a December 2025 merger agreement, BioMarin will acquire Amicus for $14.50 per share in cash, after which Amicus will become a wholly owned subsidiary and its stock will cease trading publicly, contingent on shareholder and regulatory approvals.
Commercial performance is led by Fabry drug Galafold, which generated $521.7 million in 2025 revenue, up $63.6 million year over year, and Pompe therapy Pombiliti + Opfolda, with $112.5 million in 2025 revenue, an increase of $42.3 million. Cash, cash equivalents and marketable securities totaled $293.5 million as of December 31 2025, supporting ongoing commercialization and pipeline work, including the U.S. license for Phase 3 kidney candidate DMX‑200. The company also emphasizes extensive patent protection, global regulatory approvals, and a long list of risk factors spanning merger completion, competition, pricing, regulation, financing needs, and reliance on third parties.
Amicus Therapeutics reported strong full-year 2025 growth and highlighted its pending acquisition by BioMarin. Net product revenue reached $634.2 million, up 20% year-over-year (17% at constant exchange rates), driven by Galafold at $521.7 million and Pombiliti + Opfolda at $112.5 million.
GAAP results improved to a net loss of $27.1 million, compared with larger losses in prior years, while non-GAAP net income was $96.8 million, or $0.31 per basic and diluted share. Cash and investments totaled $294 million, an increase of $44 million in 2025, and total assets were $949.9 million with stockholders’ equity of $274.2 million at year-end.
The company reiterated that the proposed acquisition by BioMarin is expected to close in Q2 2026, subject to closing conditions and approvals. Given the pending transaction, Amicus is not providing 2026 financial guidance and will not host its regular quarterly earnings conference call, directing investors instead to materials on its investor relations website.
Amicus Therapeutics, Inc. received an amended Schedule 13G/A (Amendment No. 3) from Wellington Management Group LLP and related entities reporting a small ownership stake in its common stock as of 12/31/2025.
The Wellington entities report beneficial ownership of 1,373,867 Amicus common shares, representing about 0.44% of the outstanding class. They have no sole voting or dispositive power, but report shared voting power over 1,034,976 shares and shared dispositive power over 1,373,867 shares.
The securities are owned of record by investment advisory clients of the Wellington investment advisers. Wellington certifies the holdings are maintained in the ordinary course of business and not for the purpose of changing or influencing control of Amicus Therapeutics.
Amicus Therapeutics, Inc. received an amended Schedule 13G from William Blair Investment Management, LLC reporting its beneficial ownership of the company’s common stock. William Blair reports beneficial ownership of 10,627,717 shares of Amicus common stock, representing 3.4% of the outstanding shares as of 12/31/2025.
The firm has sole power to vote 10,321,526 shares and sole power to dispose of 10,627,717 shares, with no shared voting or dispositive power. William Blair certifies that the shares were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Amicus Therapeutics.
Amicus Therapeutics has agreed to be acquired by BioMarin Pharmaceutical in an all-cash merger. Amicus stockholders are being asked to approve a Merger Agreement under which Lynx Merger Sub 1, a BioMarin subsidiary, will merge into Amicus, which will become a wholly owned BioMarin subsidiary.
At closing, each share of Amicus common stock will be converted into the right to receive $14.50 in cash per share, subject to applicable tax withholding and excluding shares with properly perfected appraisal rights. A virtual special meeting will be held on March 3, 2026, and holders of Amicus common stock at the January 28, 2026 record date may vote. The board unanimously recommends voting FOR the merger, the advisory compensation proposal, and the adjournment proposal. If approved and completed, Amicus will be delisted from Nasdaq, and stockholders will cease to own Amicus shares.
Amicus Therapeutics provided preliminary, unaudited 2025 financial estimates in connection with its proposed acquisition by BioMarin Pharmaceutical. As of December 31, 2025, Amicus estimates it held approximately $294 million in cash, cash equivalents and marketable securities. For the year ended December 31, 2025, it estimates total net product revenues of about $634 million, including roughly $522 million from Galafold® and $112 million from Pombiliti® + Opfolda®.
The company stresses these figures are preliminary, unaudited and subject to normal closing procedures, with its auditor Ernst & Young LLP providing no assurance. Amicus warns that actual results may differ, that the estimates do not include all information needed to understand full-year performance, and that they should be read together with risk factor and forward‑looking statement disclosures, especially in the context of the pending merger and related shareholder vote.
Amicus Therapeutics President and CEO Bradley L. Campbell reported an option exercise and share sale. On January 20, 2026, he exercised 75,000 stock options with an exercise price of $6.10 per share, receiving 75,000 shares of common stock. That same day, he sold 75,000 shares of common stock at a weighted average price of $14.3091 per share, with individual sale prices ranging from $14.30 to $14.32.
Following these transactions, Campbell directly owned 1,021,180 shares of Amicus Therapeutics common stock. All options exercised were fully vested and exercisable as of the transaction date. The filing notes that all transactions were carried out under a Rule 10b5-1 trading plan adopted on September 12, 2025.
Amicus Therapeutics, Inc. (FOLD) has agreed to be acquired by BioMarin Pharmaceutical Inc. in an all-cash merger at $14.50 per share. Lynx Merger Sub 1, Inc., a BioMarin subsidiary, will merge into Amicus, which will become a wholly owned BioMarin subsidiary.
After the merger, Amicus stock will be delisted from Nasdaq and deregistered, and stockholders will receive only the cash merger payment or, if properly perfected, an appraisal-based cash amount determined by the Delaware Court of Chancery. The deal requires approval by holders of a majority of Amicus’ outstanding common stock at a virtual special meeting in 2026, and a $175 million cash termination fee may be payable to BioMarin if the agreement ends under specified circumstances.
The board unanimously determined the merger is advisable and fair to stockholders and recommends voting “FOR” the merger agreement, the advisory compensation proposal, and the adjournment proposal.
Amicus Therapeutics insider plans Form 144 stock sale. A person identified through a 10b5-1 sales plan for Bradley Campbell filed notice to sell 75,000 shares of Amicus Therapeutics common stock through Morgan Stanley Smith Barney on the NASDAQ. The planned sale has an aggregate market value of $1,074,750.00 based on the figures in the notice, versus 308,533,548 Amicus common shares outstanding.
The shares to be sold were acquired on 01/20/2026 by exercising stock options from the issuer for cash on the same date. The filing also lists prior sales under the same 10b5-1 sales plan over the past three months, including 70,426 shares sold on 12/15/2025 for $763,509.39 and other smaller blocks, all in Amicus common stock.